Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
Private biotech firm Constellation Pharmaceuticals has appointed Jigar Raythatha as president and chief executive officer. 25 May 2017
Pharmaceutical
Russian R-Pharm Group together with Natsimbio, the country’s leading producer of vaccines, have reached an agreement on the establishment a joint venture for the production and sales drugs against HIV in Russia, reports The Pharma Letter’s local correspondent. 25 May 2017
Biotechnology
Colorectal cancer (CRC) exemplifies the steady progress we’ve made in cancer prevention and treatment, writes Dr Samuel Klempner, director of precision medicine at The Angeles Clinic & Research Institute, in the first oncology-themed Expert View piece being published around this year's ASCO Annual Meeting. 25 May 2017
Biotechnology
Shares in US biotech firm Alexion Pharmaceuticals slumped nearly 10% today as investors were unsettled by a raft of management changes from new chief executive Ludwig Hantson. 24 May 2017
Pharmaceutical
In the run up to the annual meeting of the American Society of Clinical Oncology, we present the first of three analyses focusing on the state of cancer research and care. This week, our correspondent Simon Wentworth reviews progress in the much-anticipated field of precision oncology. 23 May 2017
Biotechnology
British biotech firm Summit Pharmaceuticals has made several key appointments in its research and development unit. 23 May 2017
Biotechnology
While drug developers deserve credit for the enormous progress achieved in hepatology, use of the word ‘cured’ can perhaps be seen as unhelpful given that global statistics paint a very different picture of the impact of viral hepatitis. 22 May 2017
Pharmaceutical
During the late 1960s and early 1970s, Japanese style management was venerated in business schools and books as the way to build successful enterprises. Japanese companies validated this assumption by capturing worldwide market share in diverse products, such as automobiles and electronics, writes P Reed Maurer, long time pharma industry watcher who is president of International Alliances Limited, in his regular exclusive insight for The Pharma Letter. 22 May 2017
Generics
Prices for drugs from low and middle-priced segments of the Russian market may increase significantly this year, due to plans of the government to change the scheme of pricing for such categories of drugs, starting from January 1, 2018, reports The Pharma Letter’s local correspondent. 19 May 2017
Pharmaceutical
Major drug makers in India are in a soup. It is not just the US Food and Drug Administration that is cracking the whip given its three-fold increase in scrutiny of pharma units, the National Pharmaceutical Pricing Authority (NPPA) has issued ‘show cause’ notices to 67 drug companies for introducing certain new brands without price approval, reports The Pharma Letter’s India correspondent. 18 May 2017
Pharmaceutical
Sweden-based specialty pharma company Pharmalink has announced the appointment of Renee Aguiar-Lucander as its new chief executive. 18 May 2017
Pharmaceutical
The cost of the clinical trial process today is upwards of $100 million. So how can drug developers with robust research and development (R&D) pipelines but a limited operating budget make the most of their portfolios and get as many promising new therapies to market in the narrow window before patents expire, asks Ben van der Schaaf, principal at management consulting firm Arthur D. Little in an expert view piece. 17 May 2017
Biotechnology
With a global society of researchers, regulators and clinicians celebrating its 25th anniversary, 2017 is a good time to consider how cellular therapies have progressed in this period, where they are now, and the obstacles preventing their advance in the next quarter-century. 16 May 2017
Biotechnology
Actelion has detailed changes to its management team that will come into effect once the Swiss biotech firm becomes part of Johnson & Johnson. 16 May 2017
Pharmaceutical
UK-based GW Pharmaceuticals has appointed Volker Knappertz as chief medical officer (CMO). 15 May 2017
Pharmaceutical
To create a more innovation – friendly environment for the pharma industry, the Chinese Food and Drug Administration CFDA) recently released two drafts for public opinion until June 10, reports The Pharma Letter’s China correspondent Wang Fangquing. 15 May 2017
Pharmaceutical
French pharma major Sanofi has announced it is ready to start supplying insulin, which is produced at its factory in the Russian Orel region, to the European market, reports The Pharma Letter’s local correspondent. 15 May 2017
Pharmaceutical
The ever increasing prices for drugs in Russia could be explained by the existing cartels, which have been created in the domestic pharmaceutical market by some global drugmakers and their distributors, according to recent statements of Igor Artemiev, head of the Russian Federal Antimonopoly Service (FAS). 15 May 2017
Pharmaceutical
Germany’s Merck KGaA has appointed Constantin Birnstiel as head of group communications. 12 May 2017
Pharmaceutical
Japan’s Astellas Pharma has promoted Shontelle Dodson to senior vice president and head of medical affairs Americas, effective May 15, 2017. Ms Dodson previously served as vice president of medical excellence within the global medical affairs organization. 12 May 2017
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze